Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemoporfin PDT in Children with Port-wine Stain
NCT03125057Phase 4Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Aug 2017
- Primary completion
- May 2020
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, single-blind trial of hemoporfin in port-wine stain (2 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoint: Response rate at 8 weeks. Started Aug 2017; status: completed.
02
Drugs
hemoporfin
03
Conditions
port-wine stain
Beyond the preview
Go deeper on NCT03125057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125057.